Home >  News >  Industry >  Pharma News >  DFE Pharma launches new...

DFE Pharma launches new Center of Excellence in Hyderabad

C2F capabilities also support efficiency projects such as conversion from wet granulation to direct compression.;

By - Ruchika Sharma
Published On 2022-05-29 05:30 GMT   |   Update On 2022-05-29 05:30 GMT
Advertisement

Hyderabad: DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, on Thursday announced the launch of its new Center of Excellence (CoE) "Closer to the Formulator" (C2F) in Hyderabad, Telangana.

The C2F center is based at Genome Valley in Hyderabad, a hub of major Indian and global (bio) pharmaceutical companies and renowned research organizations.
C2F helps pharmaceutical companies to shorten the time from a concept to a finished commercial product through expertise in all phases of pharmaceutical development.
Pharmaceutical companies face increasing challenges such as developing robust formulations which can be scaled up for high-speed production and first launched in the market.
The services offered by this new state-of-the-art facility, are mainly focused on oral solid dosage forms, comprising all types of pre-registration work including development, scale-up, and technology transfer.
Formulation support includes specialized dosage forms such as orally disintegrating, effervescent, chewable, and sublingual tablets, mini tablets.
Advertisement
C2F capabilities also support efficiency projects such as conversion from wet granulation to direct compression.
The center works with the active pharmaceutical ingredients (APIs)* and can utilize innovative concepts with model APIs. The equipment covers an instrumented tablet press, an automated capsule filling machine, a tablet coater, a blister packaging machine, stability chambers, and state-of-the-art analytical equipment.
The C2F offering can provide pharmaceutical companies with multiple advantages such as, for example, the aim to significantly lower the number of development cycles and to reduce formulation costs when launching a medicine.
Telangana Minister for Industries and Municipal Administration and Urban Development, Mr K.T. Rama Rao, said: "I'm delighted to welcome DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions in Genome Valley, Hyderabad.
We are happy to support and facilitate the establishment of "Closer to the Formulator" (C2F) with the major objective of helping pharma companies to move up the value chain, he said.
The Government of Telangana will work with DFE Pharma to ensure that Life Sciences companies in the state leverage this facility, he added.
Headquartered in Goch, Germany, DFE Pharma has made a multimillion-euro investment in the new Center in Hyderabad and our overall goal is to help the global and Indian pharmaceutical industry to launch new products fast, at a low cost, and always first-time-right" said Martti Hedman, CEO of DFE Pharma.
"This new Center of Excellence demonstrates how DFE Pharma anticipates trends and innovations to increase patient's access to safe, high-quality medicines", Hedman added.
"Our new C2F center of nearly 1200 m2, offers cutting-edge capabilities and resources to improve product development globally, while also integrating hardware and data management software. Our services result in robust formulations, utilizing top-level excipient expertise transferrable to scale-up. We aim to further collaborate with our customers in this new Center to combine the joint formulation expertise" explained Dr. Anilkumar S. Gandhi, Director of the C2F center.

Read also: Hyderabad: Ferring Pharma to establish new manufacturing unit for Pentasa

Tags:    
Article Source : UNI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

CDSCO Panel Defers Biosphere's Colloidal Nano Silver Gel Trial, Seeks Full Data

Fake WHO, Abbott Emails Used in Over Rs 1.1 Crore Scam on Pharma Executive, 2 Nabbed

State Drug Alert: Ciprofloxacin, Lorazepam, Albendazole Among 97 NSQ Samples Flagged in July

USFDA approves Teva Pharma generic Saxenda for weight loss

AbbVie to buy Gilgamesh Pharma Bretisilocin for Major Depressive Disorder

GSK Gepotidacin approved in UK for UTIs in females aged 12 years and older

AstraZeneca Imfinzi application granted priority review by USFDA for resectable early stage gastric, gastroesophageal junction cancers

46 Drug Batches Fail CDSCO Quality Test In July, Details